Training activity information
Details
Analyse and interpret results for a range of triplet repeat assays for paediatric patients, as examples:
- Myotonic dystrophy
- Fragile X
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- What specific knowledge do you need to have before analysing and interpreting results for Myotonic dystrophy and Fragile X? Think about the genetic basis of these conditions, the technical aspects of triplet repeat assays, and the typical results you might expect to see.
- What actions will you take to prepare for this experience? Will you review relevant literature on Myotonic dystrophy and Fragile X? Will you discuss previous examples of triplet repeat assay results with your training officer?
- What possible challenges might you encounter when analysing and interpreting these results? Consider potential issues with data quality, ambiguous results, or the need to consider family history. How might you handle these challenges?
In action
- How are you currently approaching the analysis of the triplet repeat assay data for Myotonic dystrophy and Fragile X? Why are you choosing this particular method or sequence of steps?
- How are you interpreting the results? For instance, how are you determining if the number of repeats falls within a normal, intermediate, or pathogenic range?
- How effective are your current strategies in identifying potential pathogenic expansions or unusual repeat patterns associated with Myotonic dystrophy and Fragile X?
- What challenges are you encountering in this moment, such as ambiguous repeat sizes, technical artefacts, or the presence of somatic mosaicism?
- What can you learn from the data as it unfolds? Are there any unexpected findings or patterns emerging that you need to investigate further?
- Are there alternative analysis or interpretation approaches you could consider if your initial assessment is unclear or if you encounter discrepancies?
- Are you ensuring that your interpretation remains within the scope of established laboratory protocols and your level of training and ability?
On action
- Begin by summarising the key aspects of the experience.
- What were the main types of triplet repeat assays you analysed?
- What were the range of results you encountered (e.g., normal, intermediate, pathogenic)?
- Were there any unusual or unexpected results?
- What specific skills or knowledge did you develop or improve through analysing these triplet repeat assay results?
- Did you enhance your understanding of the repeat ranges for Myotonic dystrophy and Fragile X?
- Did you become more proficient in using specific analysis tools or guidelines?
- Were there any unexpected challenges or successes during the activity? What did you learn from these? For example, did you encounter any ambiguous results that required further investigation?
- Did you successfully identify a pathogenic expansion in a sample that was initially challenging to interpret?
- What areas for continued development have been identified as a result of this activity? For instance, do you need to further enhance your understanding of somatic mosaicism in triplet repeat disorders?
- Do you need more practice in differentiating between different types of repeat expansions?
- How can you apply the learning from this activity to your routine practice?
- Will you incorporate any new strategies or resources into your approach to analysing triplet repeat assays?
- What do you need to do to develop further in this area e.g. explore relevant literature, discuss specific cases with colleagues, or seek further training on a particular aspect of triplet repeat analysis.
- What support or resources might you need to further develop in the areas identified through this reflection? Do you need access to specific databases, guidelines, or expert mentorship?
Beyond action
- Have you revisited the experiences of analysing and interpreting triplet repeat assays for Myotonic dystrophy and Fragile X? Have your interpretations or understanding of these assays changed since you first completed the activity?
- Has your approach to dealing with complex or borderline results evolved?
- How do your experiences with triplet repeat assays connect with your understanding of other PCR-based or fragment analysis techniques?
- How has your understanding of the technical aspects and the clinical implications of triplet repeat disorders developed since this activity?
- How have you developed your skills in interpreting these assays? How has experience since influenced your wider practice in the laboratory? For example, has it influenced how you approach quality control or the review of SOPs?
- Identify clear actions for continued development of the skills introduced through these activities. For example, do you plan to attend any workshops or read specific articles to further your understanding of new developments in triplet repeat testing?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 2 |
Outcome
Perform targeted analysis for patients referred with paediatric conditions. |
| # 5 |
Outcome
Interpret and report genomic testing relevant to paediatric conditions, including appropriate recommendations for patient management. |